- Patent advances Dewpoint’s leadership in the discovery of biomolecular condensate modulators with vast potential to treat disease
- The new technology is the first to measure how a compound enters or distributes in a condensate to selectively target a single molecule to modify disease
BOSTON, November 14, 2022 /PRNewswire/ — Dewpoint Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued the patent “Methods of Characterizing Condensate-Associated Characters of Compounds and Uses of There” (US Patent No. 11493519) covering a novel separation technology and identification of compounds that preferentially partition into condensates of interest.
Biomolecular condensates are molecular assemblies that form through a process called phase separation, similar to the separation of oil from water. Various condensates are known to be important in modulating cellular processes and regulating many diverse functions of the cell, from controlling biochemical reaction rates to compartmentalizing proteins and nucleic acids in the orchestrated transcriptional machinery. Aberrant condensate function has also been linked to human diseases, including neurodegeneration and cancers. Condensate science holds great promise both for understanding the origin of disease and for discovering breakthrough treatments.
Little is known about the mechanisms governing the partitioning of compounds into condensates, how to design and test compounds to improve interactions with condensates, and how this information can be used to improve disease treatment.
The patent issued by Dewpoint is the first patented technology to measure how a compound enters or distributes in a target condensate. This breakthrough technology will direct a compound to selectively target a single molecule in a condensate to modify disease.
“Dewpoint’s technology has broad implications for drug discovery and maximizing drug efficacy,” said isaac klein, MD, Ph.D., Scientific Director at Dewpoint. “This opens up a new era of ‘condensate-targeted’ drug discovery by allowing us to direct a molecule to a condensate of interest. This can influence a drug’s activity by altering its local subcellular concentration and, therefore, its efficacy. It’s a new way of thinking about medicinal chemistry and optimizing leads with the potential to improve drug efficacy.”
In May 2022, Dewpoint was awarded a USPTO Foundational Platform Technology patent, for technology that identifies molecules that modify specific components of biomolecular condensates with high precision. Together, these patents claim technology essential to the discovery of new compounds that can be used to disrupt a condensate in specific ways to correct aberrant cellular functions and hold vast therapeutic potential.
About Dewpoint Therapeutics
Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint believes that a wide range of conditions have pathways that are condensate regulated or result from condensate malfunction.
Dewpoint currently has more than 20 development programs in an ambitious pipeline with programs spanning oncology, neuromuscular, cardiopulmonary and virology indications, and collaborations with leading global academic and pharmaceutical partners including Bayer, Merck and Pfizer. Dew point scientists work in BostonDresden and Frankfurt translating condensate biology into breakthrough treatments for diseases previously thought to be incurable.
Learn more at dewpointx.com and follow us on Twitter and LinkedIn.
Scientists or investors interested in biomolecular condensates can also visit condensates.com for news and updates in the field.
Vice President, Head, Communications and Public Relations
Dew point therapy
+1 609-439-3997 | [email protected]
SVP, Corporate Development and Investor Relations
Dew point therapy
SOURCE Dew Point Therapy